Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate.
Status:
Active, not recruiting
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate in
the treatment of subjects with congenital AT-III deficiency.